ABSTRACT
The oncology patient with HIV infection presents unique problems and challenges. When considering antineoplastic chemotherapy, a balance must be struck between the therapeutic effects on the malignancy and the potential for worsening human immunodeficiency virus (HIV)-associated immunosuppression. Ideally, one would like to maximize the antitumor benefit while sparing the immune system from both the detrimental effects of chemotherapy and the progressive immune injury of HIV. However, many questions remain for how best to achieve these goals. In this chapter, we will attempt to review some of what is presently known in this field, to see what conclusions may now be drawn, and to articulate some of the areas for further research.
